Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol A Nelson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 2014
The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenograftsCarol A Nelson, Michael T Azure, Christopher T Adams, et al.
Calcified Tissue International|July 11, 2016
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic RatsHila Bahar, Kyla Gallacher, Julie Downall, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 24, 2015
Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndromeJason R Cook, Nicholas P Clayton, Luca Carta, et al.
Journal of Medicinal Chemistry|February 24, 2007
Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studiesJohn E Cyr, Daniel A Pearson, David M Wilson, et al.
Journal of Medicinal Chemistry|August 19, 2007
Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agentJohn E Cyr, Daniel A Pearson, Carol A Nelson, et al.
Molecular Therapy. Nucleic Acids|October 29, 2014
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe DiseaseNicholas P Clayton, Carol A Nelson, Timothy Weeden, et al.
Nucleic Acid Therapeutics|January 12, 2013
Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophyAndrew J Leger, Leocadia M Mosquea, Nicholas P Clayton, et al.
The American Journal of Pathology|June 7, 2011
Inhibiting TGF-β activity improves respiratory function in mdx miceCarol A Nelson, R Bridge Hunter, Lindsay A Quigley, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 2014
The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenograftsCarol A Nelson, Michael T Azure, Christopher T Adams, et al.
Calcified Tissue International|July 11, 2016
Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic RatsHila Bahar, Kyla Gallacher, Julie Downall, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 24, 2015
Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndromeJason R Cook, Nicholas P Clayton, Luca Carta, et al.
Journal of Medicinal Chemistry|February 24, 2007
Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studiesJohn E Cyr, Daniel A Pearson, David M Wilson, et al.
Journal of Medicinal Chemistry|August 19, 2007
Isolation, characterization, and biological evaluation of syn and anti diastereomers of [(99m)Tc]technetium depreotide: a somatostatin receptor binding tumor imaging agentJohn E Cyr, Daniel A Pearson, Carol A Nelson, et al.
Molecular Therapy. Nucleic Acids|October 29, 2014
Antisense Oligonucleotide-mediated Suppression of Muscle Glycogen Synthase 1 Synthesis as an Approach for Substrate Reduction Therapy of Pompe DiseaseNicholas P Clayton, Carol A Nelson, Timothy Weeden, et al.
Nucleic Acid Therapeutics|January 12, 2013
Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophyAndrew J Leger, Leocadia M Mosquea, Nicholas P Clayton, et al.
The American Journal of Pathology|June 7, 2011
Inhibiting TGF-β activity improves respiratory function in mdx miceCarol A Nelson, R Bridge Hunter, Lindsay A Quigley, et al.
Pageof 1